These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. Hudson M; Richard H; Pilote L BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399 [TBL] [Abstract][Full Text] [Related]
4. Lessons on prescribing and drug safety from the withdrawal of rofecoxib. Nelson M; Cicuttini F Aust Fam Physician; 2004 Dec; 33(12):965-6. PubMed ID: 15630913 [No Abstract] [Full Text] [Related]
5. Simultaneous presentation of rofecoxib-induced acute hepatitis and acute interstitial nephritis. Haider M; Gain E; Khadem G; Pilmore H; Yun K; Jayasinghe N; Walker R Intern Med J; 2005 Jun; 35(6):370-2. PubMed ID: 15892770 [No Abstract] [Full Text] [Related]
6. COX-2 inhibitors and risk of heart failure. Kammerl MC; Debler J; Riegger GA; Krämer BK Lancet; 2004 Oct 23-29; 364(9444):1486-7; author reply 1487. PubMed ID: 15500886 [No Abstract] [Full Text] [Related]
7. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Carné X; Cruz N Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277 [No Abstract] [Full Text] [Related]
8. The great rofecoxib feeding frenzy. Van Way CW JPEN J Parenter Enteral Nutr; 2005; 29(2):136-8. PubMed ID: 15772394 [No Abstract] [Full Text] [Related]
9. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)]. Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531 [TBL] [Abstract][Full Text] [Related]
10. Probable rofecoxib-induced thrombocytopenia. Kentos A; Robin V; Lambermont M; Jurdan M; Pignarelli M; Feremans W Rheumatology (Oxford); 2003 May; 42(5):699-700. PubMed ID: 12709555 [No Abstract] [Full Text] [Related]
11. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Bagán JV; Thongprasom K; Scully C Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219 [TBL] [Abstract][Full Text] [Related]
12. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772 [TBL] [Abstract][Full Text] [Related]
13. Intracranial hypertension induced by rofecoxib. Jacob S; Rajabally YA Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617 [TBL] [Abstract][Full Text] [Related]
14. [Gynecomastia secondary to rofecoxib]. Martínez JA; Tejada González P; Gutiérrez Sanpedro N; González Blanco P Med Clin (Barc); 2002 Jun; 118(20):798-9. PubMed ID: 12049701 [No Abstract] [Full Text] [Related]
15. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. Bijlsma JW Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407 [TBL] [Abstract][Full Text] [Related]
16. Severe cholestasis and acute renal failure related to rofecoxib. Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886 [No Abstract] [Full Text] [Related]
17. The Vioxx debacle. Alpert JS Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713 [No Abstract] [Full Text] [Related]